Covis drug porfolio
when it was bought..it doubled cxr's revenue to approx 180 million annually. The portfolio has 20 proven drugs and will continue to produce revenue with generics. Nilandron is a prostate cancer drug that is very effective and a grneric version is going to be launched by concordia next month. I am sure both the branded and the generic version will dominate market share for that particular drug.i think the write down wad overly done and we might see an adjustment to equity in the future. Lanoxin, another drug from the same portfolio is performing very well. A huge amount of revenue is being generated from this portfolio and if it continues for at least the next 5 to 8 years they will make significant progress in paying down that portion of the debt from these drugs. AMCO on the other hand is growing at 8% per quarter for the past year. 60 new drugs will keep that revenue stable and also grow . Donnatal was bought for 320 million and i think they have produced more the 200 million in revenue from it in the past 2 years. The past few months wow scripts are indicating that it is a stable drug and is producing good revenues. I think the cash position if 480 million with another 200 million revolver and 200 million plus in accounts recievables makes this a very stable company . At these liquidation values , i would have no problem buying more shares and play it as a long term investment